Skintelligence

Company Overview

Snapshot

Founded in April 2018 by Miriam Oron and Guy Shalom, Skintelligence operated with 1–10 employees. The company secured a grant from the Israel Innovation Authority in December 2018, a key milestone in its early development.

Business overview

Skintelligence developed clinical decision support systems (CDSSs) leveraging artificial intelligence to predict individual responses to biological therapy, particularly for autoimmune diseases like psoriasis, rheumatoid arthritis, and Crohn's disease. The company's core technology, SmartPAD, integrated non-invasive immunologic biomarker measurements from the skin with clinical data to calculate treatment success probabilities. This solution aimed to reduce the trial-and-error process in prescribing biological medications, thereby lowering costs and patient discomfort. Skintelligence operated within the Digital Health and Medical Technologies sector, targeting pharmaceutical companies, clinics, and insurance providers.

Company Intelligence Q&A

What is Skintelligence's primary focus?

Skintelligence specializes in developing clinical decision support systems (CDSSs) that utilize artificial intelligence to predict patient responses to biological therapies for autoimmune diseases such as psoriasis, rheumatoid arthritis, and Crohn's disease.

Who founded Skintelligence?

Skintelligence was founded by Miriam Oron and Guy Shalom in April 2018.

What was the purpose of the SmartPAD product?

SmartPAD (SMART Predictor for Autoimmune Diseases) was a patented device and software system designed by Skintelligence to measure immunologic biomarkers from the skin using non-invasive assays. It integrated these biomarkers with clinical data to calculate the probability of treatment success with commercial biological drugs.

When did Skintelligence cease operations?

Skintelligence ceased to operate in December 2021.

Did Skintelligence receive any grants?

In December 2018, Skintelligence secured a grant from the Israel Innovation Authority.